Geron Corp GERN:NASDAQ

Last Price$2.36Cboe Real-Time Last Sale as of 2:44PM ET 8/15/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.01(0.43%)
Bid (Size)$2.37 (1,645)
Ask (Size)$2.38 (1,200)
Day Low / High$2.32 - 2.45
Volume1.9 M
 

View Biotechnology IndustryPeer Comparison as of 08/15/2022

 

Geron Corp ( NASDAQ )

Price: $2.36
Change: +0.01 (0.43%)
Volume: 1.9 M
2:44PM ET 8/15/2022
 
 

Anavex Life Sciences Corp ( NASDAQ )

Price: $11.87
Change: +0.22 (1.89%)
Volume: 319.7 K
2:45PM ET 8/15/2022
 
 

Stoke Therapeutics Inc ( NASDAQ )

Price: $21.22
Change: -0.38 (1.76%)
Volume: 63.1 K
2:38PM ET 8/15/2022
 
 

Cogent Biosciences Inc ( NASDAQ )

Price: $14.42
Change: +0.29 (2.05%)
Volume: 958.4 K
2:46PM ET 8/15/2022
 
 

Altimmune Inc ( NASDAQ )

Price: $17.37
Change: +0.01 (0.06%)
Volume: 855.6 K
2:44PM ET 8/15/2022
 

Read more news Recent News

Update: Geron Reports Narrower Q2 Loss, Lower Revenue; Shares Advance Friday
12:06PM ET 8/12/2022 MT Newswires

(Story updated to include stock move in the headline and last paragraph.) Geron (GERN) reported a Q2 net loss of $0.07 per diluted share late Thursday,...

--Needham & Co Adjusts Geron Price Target to $3 From $2, Maintains Buy Rating
12:00PM ET 8/12/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Geron Reports Narrower Q2 Loss, Revenue Declines; Shares Rise in Premarket
8:05AM ET 8/12/2022 MT Newswires

Geron (GERN) reported a Q2 net loss of $0.07 per diluted share late Thursday, compared with a loss of $0.09 per share a year earlier. Analysts polled by...

--B. Riley Resumes Geron at Buy with $4 Price Target, Says Thesis Hinges on Potential Success of Imetelstat
9:57AM ET 7/28/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

Geron Corporation's (GERN) CEO Dr. John Scarlett on Q2 2022 Results - Earnings Call Transcript
8:27PM ET 8/11/2022 Seeking Alpha

Geron Corporation 2022 Q2 - Results - Earnings Call Presentation
8:09PM ET 8/11/2022 Seeking Alpha

Geron: Waiting For Godot
2:55PM ET 7/15/2022 Seeking Alpha

VERU's Shares Jump on Successful COVID-19 Study Results
10:44AM ET 7/08/2022 Zacks

VERU gains on the success of its late stage study evaluating the efficacy and safety of oral...

Company Profile

Business DescriptionGeron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA. View company web site for more details
Address919 East Hillsdale Boulevard
Foster City, California 94404
Phone+1.650.473.7700
Number of Employees17
Recent SEC Filing08/11/2022S-8
Chairman, President & Chief Executive OfficerJohn A. Scarlett
Chief Operating Officer & Executive Vice PresidentAndrew J. Grethlein
Chief Financial Officer, Treasurer & Executive VPOlivia K. Bloom
Chief Medical Officer & Executive Vice PresidentFaye Feller

Company Highlights

Price Open$2.36
Previous Close$2.35
52 Week Range$0.99 - 2.67
Market Capitalization$891.7 M
Shares Outstanding377.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/08/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.34
Beta vs. S&P 500N/A
Revenue$1.1 M
Net Profit Margin-8,693.61%
Return on Equity-90.38%

Analyst Ratings as of 07/27/2022

Buy
4
Overweight
1
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset